Ticker Symbol: TCRX
Tscan Therapeutics Inc
$8.51 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001783328
Company Profile
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
Website: www.tscan.com
CEO: N/A
Tags:
N/A
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $3.37
Change:
-$0.13
(
-3.71%)
Days Range: $3.29 - $3.54
Beta: -
52wk. High: $6.03
52wk. Low: $1.45
Ytd. Change 122.09%
50 Day Moving Average: $2.93
200 Day Moving Average: $2.59
Shares Outstanding: 43542178
Valuation
Market Cap: 14.7B
PE Ratio: -1.23
EPS (TTM): -2.73
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A